Trial reportAmerican journal of nephrology2010
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.
Trial report in American journal of nephrology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.Cancer chemotherapy and pharmacology · 2022Pooled it
- Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review.BMC medicine · 2013Pooled it
- Trial
- Pharmacogenomics-guided therapy for essential hypertension: a multi-center randomized controlled open-label trial.Frontiers in cardiovascular medicine · 2026Article
- Associations Between CYP3A5 (c.6986A>G) Gene Polymorphism and Kidney Impairment in Hypertensive Adults Without Cystatin C Elevation.Cardiovascular toxicology · 2024Article
- Genetic Variation inJournal of personalized medicine · 2024Article
- Pharmacogenomics assists in controlling blood pressure in cardiovascular and cerebrovascular patients during Rehabilitation: a case report.Frontiers in pharmacology · 2024Article
- Genetic Variation inPharmaceutics · 2023Article
- Pharmacogenomics of Hypertension in Africa: Paving the Way for a Pharmacogenetic-Based Approach for the Treatment of Hypertension in Africans.International journal of hypertension · 2023Review
- The Role of CYP3A in Health and Disease.Biomedicines · 2022Review
- Management of Hypertension in the Elderly and Frail Patient.Drugs & aging · 2022Article
- Article
- Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer.Biomedicines · 2021Review
- Association ofPharmacogenomics and personalized medicine · 2021Article
- Race and genetics versus 'race' in genetics: A systematic review of the use of African ancestry in genetic studies.Evolution, medicine, and public health · 2021Review
- Pharmacogenomics of Hypertension Treatment.International journal of molecular sciences · 2020Review
- A review of clinical pharmacogenetics Studies in African populations.Personalized medicine · 2020Review
- Sickle Cell Anemia: Variants in theFrontiers in pharmacology · 2020Article
- Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review.Heart failure reviews · 2019Review
- Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects.Pharmacogenomics and personalized medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 11 institutions in 2 countries.
Funding
Abstract
purposeTo explore the association between CYP3A4 and CYP3A5 gene polymorphisms and blood pressure response to amlodipine among participants from the African-American Study of Kidney Disease and Hypertension Trial randomized to amlodipine (n = 164).
methodsCox proportional hazards models were used to determine the risk of reaching a target mean arterial pressure (MAP) of < or =107 mm Hg by CYP3A4 (A-392G and T16090C) and CYP3A5 (A6986G) gene polymorphisms, stratified by MAP randomization group (low or usual) and controlling for other predictors for blood pressure response.
resultsWomen randomized to a usual MAP goal with an A allele at CYP3A4 A-392G were more likely to reach a target MAP of 107 mm Hg. The adjusted hazard ratio (AA/AG compared to GG) with 95% confidence interval was 3.41 (1.20-9.64; p = 0.020). Among participants randomized to a lower MAP goal, those with the C allele at CYP3A4 T16090C were more likely to reach target MAP: The adjusted hazard ratio was 2.04 (1.17-3.56; p = 0.010). After adjustment for multiple testing using a threshold significance level of p = 0.016, only the CYP3A4 T16090C SNP remained significant. CYP3A5 A6986G was not associated with blood pressure response.
conclusionsOur findings suggest that blood pressure response to amlodipine among high-risk African-Americans appears to be determined by CYP3A4 genotypes, and sex specificity may be an important consideration. Clinical applications of CYP3A4 genotype testing for individualized treatment regimens warrant further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.